Roth Capital Cuts PT on Heat Biologics (HTBX) by ~27% Following HS-410 Phase 2 Data

December 1, 2016 8:25 AM EST
Get Alerts HTBX Hot Sheet
Price: $0.89 -1.11%

Rating Summary:
    4 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 23 | Down: 37 | New: 34
Trade HTBX Now!
Join SI Premium – FREE

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Roth Capital cuts its price target on Buy-rated Heat Biologics (Nasdaq: HTBX) from $2.75 to $2 following adverse HS-410 combo phase 2 data in bladder cancer, as announced on Wednesday night.

Analyst Joseph Pantginis commented today, Based on the outcome of the Phase II study, reality or perception is the driver here in that the HS-410 study failed. The potential "grey" area is that: 1) the data would have swung dramatically with only two or three patients, 2) strong immune responses from vaccine are observed, 3) many patients on curves are censored and further follow up could play out positively. In the meantime, next week's DURGA readout could provide some potential salvation with topline data (n~9) from the Phase Ib DURGA study combining HS-110 + Opdivo in NSCLC.

For an analyst ratings summary and ratings history on Heat Biologics click here. For more ratings news on Heat Biologics click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

Roth Capital, S1

Add Your Comment